Ironwood Pharmaceuticals
Focus: Ironwood Pharmaceuticals is a specialty pharmaceutical company headquartered in Boston focused on small molecule therapeutics, with a diversified pipeline spanning gastrointestinal, metabolic, and neurological indications.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
Open Jobs
3
Should You Work at Ironwood Pharmaceuticals?
AI assessmentIronwood is a stable, product-focused specialty pharma with runway through 2032, suitable for professionals seeking GI/metabolic expertise in a lean, specialized environment.
Why Work Here
- Two marketed products (DUZALLO and ZURAMPIC) generating peak-stage revenue with patent protection extending to 2032
- Active pipeline of 30 programs across Phase 2-4 with significant focus on GI disorders (multiple linaclotide indications) suggesting established manufacturing and clinical expertise
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
15 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Peak5.7yr
Dual xanthine oxidase inhibitor combination with 8+ years of patent protection; addresses hyperuricemia in oncology patients.
Help build intelligence for Ironwood Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.